• Member News

Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has appointed Dr David Morris MD as Chief Medical Officer to lead the Company’s respiratory programmes.

State of the Market for Directors & Officers Liability Insurance (D&O)

In Gallagher’s state of the market report published in February 2019, we wrote that we did not expect market conditions to improve for the better in 2019. Unfortunately, that prediction has held, and as we enter into Q1 2020, the Directors’ and Officers’ (D&O) insurance market remains a difficult place in which to do business.

PhoreMost strengthens leadership team with two key appointments

• Dr Catherine Beech, OBE, joins Board as a Non-Executive Director • Dr Benedict Cross joins as Senior Director (Technology)

Press release: New Cell and Gene Therapy Catapult CEO brings continuity and ambition for further impact

Matthew Durdy appointed to CEO role as the CGT Catapult prepares to accelerate innovation, growth and productivity, where needed in the UK.

Mogrify awarded $1.1M additional funding from SBRI Healthcare

• Phase II funding will be used for pre-clinical assessment of regenerative cartilage therapy • Follows Phase I SBRI funding, announced in April 2019

Coulter Partners secures Chief Scientific Officer for OxStem

Coulter Partners was very pleased to partner once again with OxStem Limited to secure the appointment of Dr. Ian Churcher to the role of Chief Scientific Officer.

Coulter Partners secures Head of US Sales for Nanoform

Coulter Partners was delighted to partner once again with innovative nanoparticle medicine enabling company, Nanoform to secure the appointment of Sally Langa as Head of US Sales. The new role will enable Nanoform to continue its rapid growth with a strengthened presence in the US market.

NEW REPORT SHOWS IMPACT OF DISCOVERY PARK COMMUNITY LAB ON STEM EDUCATION

FUTURE PLANS TO INSPIRE MORE STUDENTS & INCREASE RANGE OF ACTIVITIES

Horizon Discovery grants a multi-product use license of its GS knockout CHO K1 cell line to NGM Bio

Cell line to be used to support research and development of biotherapeutics across therapeutic areas

PhoreMost enters multi-project drug discovery collaboration with Otsuka Pharmaceutical

• PhoreMost’s next-generation phenotypic screening platform, SITESEEKER, to identify novel targets for Otsuka’s therapeutics discovery programmes • Programmes to initially focus on gene therapy applications of identified targets